Background & Aims: Current hepatitis B virus (HBV) management is challenging as treatment with nucleos(t)ide analogues needs to be maintained indefinitely and because interferon (IFN)-a therapy is associated with considerable toxicity. Previously, we showed that linking IFNa to apolipoprotein A-I generates a molecule (IA) with distinct antiviral and immunostimulatory activities which lacks the hematological toxicity of IFNa. Methods: Here, we analyse the antiviral potential of an adeno-associated vector encoding IFNa fused to apolipoprotein A-I (AAV-IA) in comparison to a vector encoding only IFNa (AAV-IFN) in two animal models of chronic hepadnavirus infection. Results: In HBV transgenic mice, we found that both vectors induced marked reductions in serum and liver HBV DNA and in hepatic HBV RNA but AAV-IFN caused lethal pancytopenia. Woodchucks with chronic hepatitis virus (WHV) infection that were treated by intrahepatic injection of vectors encoding the woodchuck sequences (AAV-wIFN or AAV-wIA), experienced only
Introduction
Chronic hepatitis B (CHB) is a global health problem, with more than 350 million individuals worldwide infected with hepatitis B virus (HBV) [1] . Available treatment options include nucleoside/nucleotide analogues (NAs) that are highly effective in suppressing HBV replication and preventing liver disease progression. However, NAs do not affect HBV RNA transcription from the covalently-closed circular DNA molecule of HBV within infected hepatocytes and, therefore, have only limited impact on HBV surface antigen serum levels. Since NAs do not directly stimulate immune clearance of HBV-infected hepatocytes, in most cases viral replication rebounds upon cessation of therapy. As a consequence, prolonged or even life-long treatment of HBV is needed. This long-lasting therapy is associated with high costs and the risk of emergence of drug resistant HBV variants [2] . Pegylated interferon alpha (PegIFNa) is an alternative therapy for CHB. This cytokine is endowed with immunostimulatory properties and targets both HBV transcription and replication. Antiviral response to PegIFNa treatment is often durable but the use of this drug is limited due to low response rates and frequent side effects that are sometimes severe [3] . Therefore, new and alternative treatment approaches for the control of CHB are warranted.
We have previously shown that the linkage of IFNa to apolipoprotein A-I (apoA-I) generates a fusion molecule termed InterApo (IA) which maintains the antiviral and immunostimulatory activities of IFNa but is devoid of the hematological and central nervous system toxicities that are mediated by this cytokine [4, 5] . In the present study, we aimed at evaluating if liver transduction with an adeno-associated virus (AAV) vector encoding IFNa (AAV-IFN) or IA (AAV-IA) is an effective therapeutic approach for chronic HBV infection. We tested this gene therapy approach in HBV transgenic (HBVTg) mice and in woodchucks with chronic woodchuck hepatitis virus (WHV) infection. The latter is a model which closely reproduces the virological and histopathological features of CHB [6] . An important difference between CHB and chronic WHV infection is that woodchucks frequently exhibit serum viral loads in excess of 10 10 viral genomes (vg)/ml while in humans HBV viremia rarely exceeds 10 7 vg/ml. The extremely high levels of circulating WHV virions cause exhaustion of immunological effectors thus rendering chronic WHV infection into a condition that is exceedingly difficult to treat. In an attempt to facilitate the response to IA, in one of our treatment protocols, we treated WHV-infected woodchucks with entecavir (ETV) during 4 weeks to see whether a transient decrease of viremia could make viral replication easier to control. Overall, our studies demonstrate that treatment with AAV-IA is safe and exerts antiviral effects both in HBVTg mice and in chronic WHV carrier woodchucks and suggest that combination of IA with NAs is a promising approach to achieve sustained control of HBV replication.
Materials and methods

Animals
Female, 6 weeks old, C57BL/6 mice were purchased from Harlan (Barcelona, Spain). The HBVTg mouse lineage 1.3.32 (inbred C57BL/6, H-2b) was kindly provided by Professor Frank Chisari (The Scripps Research Institute, La Jolla, California, USA). These HBVTg mice encode a 1.3-overlength copy of the HBV genome (serotype ayw), replicate HBV at high levels within the liver and express all of the HBV antigens [7] . HBVTg mice were matched for age (6-10 weeks), sex (male), and serum HBV DNA and HBV surface antigen levels, as determined by real-time quantitative PCR or an enzyme-linked immunosorbent assay (ELISA) (Bioelisa HBsAg 3.0, Biokit), respectively. The mice were treated in accordance with the guidelines of the University of Navarra (Pamplona, Spain). AAV vectors were inoculated in mice via retro-orbital injection in a total volume of 200 ll. For viral challenge, a lethal dose of encephalomyocarditis virus (EMCV) was intraperitoneally injected. Blood samples were drawn by retro-orbital bleeding at the indicated time points. Serum samples were derived from two consecutive centrifugations of blood samples at 9100 g for 5 minutes and stored at À20°C. Liver samples were stored at À80°C until assayed. Captive-born, 12 months old Eastern woodchucks (Marmota monax), neonatally infected with WHV were purchased from Northeastern Wildlife Inc. (Harris, ID). Animal maintenance and handling were performed according to the regulations of the local Animal Care and Use Committee of the University of Navarra. Laparotomy was performed to inject intrahepatically 2. was given at day 0 to woodchucks by intravenous injection. In both studies, blood was collected from the saphena vein or other approved sites using isoflurane or ketamine/xylazine anesthesia for sedation of woodchucks.
AAV vectors
Experiments were performed using AAV serotype 8 vectors encoding luciferase (AAV-Luc), mouse IFNa1 (AAV-IFN), the IA fusion protein generated by linking mouse IFNa1 to mouse apoA-I (AAV-IA), woodchuck IFNa5 [8, 9] (AAV-wIFN), woodchuck apoA-I [10] (AAV-wApo) or the IA fusion protein formed by linking wIFNa5 to woodchuck apoA-I (AAV-wIA). All transgenes were placed under the transcriptional control of the elongation factor 1a promoter. The above AAVs were produced by co-transfection of pDP8.ape and AAV plasmids into 293T cells [11] . Two days later, AAVs were purified from cell lysates by ultracentrifugation in Optiprep Density Gradient Medium-Iodixanol (Sigma-Aldrich, St Louis MO). For AAVs titration, viral DNA was isolated using the High Pure Viral Nucleic Acid kit (Roche Applied Science. Mannheim, Germany). The concentration of viral particles was subsequently determined by real-time quantitative PCR using primers specific to the elongation factor 1a promoter (EF-Forward (Fw): 5 0 -ggtgagtcacccacacaaagg-3 0 and EF-Reverse (Rv): 5 0 -cgtggagtcacatgaagcga-3 0 .
ELISA for murine IFNa determination
IFNa levels in serum were measured using the VeriKine™ Mouse Interferon Alpha ELISA kit (PBL, NJ, USA) by following the manufacturer's recommendations.
Hemogram
Blood samples were collected in Microvette 500 Blood Collection tubes with EDTA (Sarstedt, Landskrona, Sweden). The hemogram was analysed using the Drew Scientific HemaVet Hematology Analyser according to the manufacturer's recommendations.
RNA extraction and cDNA synthesis
Total RNA was extracted from liver tissue using the Maxwell 
Virological determinations
Serum WHV and HBV DNA was isolated using the High Pure Viral Nucleic Acid kit (Roche Diagnostics, Lewes, United Kingdom) or the QIAmp DNA Mini kit (Qiagen, Valencia, CA), respectively, and were quantified by real-time PCR as described previously [9, 12] . Serum WHV surface antigen (WHsAg) was assayed quantitatively against woodchuck serum with a known concentration of WHsAg by using a monoclonal antibody-based ELISA as described [13] . Serum HBsAg was analysed using Bioelisa HBsAg 3.0 (Biokit, Barcelona, Spain) following manufacturer's instructions.
Determination of wIFNa bioactivity
The antiviral activity mediated by wIFNa present in serum was assayed in a cytopathic effect reduction assay using woodchuck WCH17 cells following challenge with EMCV in a 96-well microtiter plate format as described previously [8] .
Statistical analysis
Statistical analyses were performed using the Prism 5 computer program (GraphPad Software Inc, San Diego, CA, USA). The survival data were represented in Kaplan-Meier graphs and analysed by the log rank test. The remaining parameters were analysed by one-way ANOVA followed by the Tukey's multiple comparisons test. The comparisons of WHV viremia and WHsAg relapse after ETV withdrawal were performed by fitting the data to a dose-response stimulation curve followed by the extra sum-of-squares F test. p <0.05 values were considered significant.
Results
IA but not IFN can be expressed in the liver for a prolonged period of time without significant hematological toxicity
We generated AAV vectors encoding IA or IFNa for evaluating the feasibility and safety of long-term expression of these molecules in rodents. As shown in Fig. 1A , immunoreactive IFNa was detected in serum of mice injected with a single dose of 5 Â 10 11 vg of AAV-IFN or AAV-IA, but IFNa levels were substantially higher with the latter vector. However, while mice treated with AAV-IA remained alive during the study period (and beyond 6 months after vector administration; data not shown), all mice that received AAV-IFN died within 60 days (Fig. 1B) . In these animals, a dramatic and significant decline in erythrocytes, leukocytes and platelets was observed while the red blood cell and platelet counts remained unchanged in AAV-IA treated mice (Fig. 1C ). Neutrophil and monocyte counts decreased significantly in mice treated with AAV-IFN but not in those which received AAV-IA while lymphocytes showed a decline in mice treated with either vector (Supplementary Fig. 1 ).
The antiviral activity of AAV-IA is comparable to that of AAV-IFN
We then analysed if the antiviral activity of AAV-IA was similar to that of AAV-IFN. To this aim, mice were injected intravenously with 5 Â 10 11 vg/mouse of AAV-IA, AAV-IFN or the control vector AAV-Luc, and 1 month later we measured the hepatic expression of IFN-stimulated genes. We found that both, AAV-IFN and AAV-IA but not AAV-Luc, stimulated the expression of IFN-stimulated genes at similar levels ( Fig. 2A ). Next, we tested the antiviral effect of AAV-IA or AAV-IFN by injecting mice with a lethal dose of EMCV. We found that animals treated with either of the two IFN-vectors were equally protected against EMCV infection provoked one month after the vector administration (Fig. 2B ). These data show that AAV-IFN and AAV-IA exhibit comparable antiviral activity but hematological toxicity is much attenuated with the latter vector. Also it should be noted that no histological changes were observed in the liver of animals 6 months after AAV-IA administration ( Supplementary Fig. 2 ).
Antiviral effects and hematological toxicity of AAV-IA and AAV-IFN in HBVTg mice
For evaluating the therapeutic effects of AAV-IA in chronic HBV infection, we tested this vector in HBVTg mice, an animal model that exhibits levels of viremia comparable to those observed in patients with CHB (7). HBVTg mice received a single dose of 1.5 Â 10 11 vg of AAV-IA, AAV-IFN or AAV-Luc control vector via the tail vein. Blood samples were collected 7 days after the AAV injection, and animals were sacrificed thereafter.
Immunoreactive IFNa was not detected in the serum of control mice (AAV-Luc) while detectable amounts of this cytokine were present in the blood of mice that received AAV-IFNa or AAV-IA (Supplementary Fig. 3 ). IFNa serum levels were higher with AAV-IA than with AAV-IFNa and both groups demonstrated a marked and significant decline in serum viral loads and in serum HBsAg in comparison to control animals (Fig. 3A) . The reduction in circulating HBV viral particles was associated with a decline in hepatic HBV DNA abundance and disappearance of HBV DNA replicative forms in the liver ( Supplementary Fig. 4 ) accompanied by a marked reduction of HBV core antigen mRNA levels in the liver (Fig. 3A) . Similarly to our observations in normal mice, leukocyte, red cell and platelet counts dropped significantly in HBVTg mice that received AAV-IFN being the descent of leukocytes and platelets significantly less pronounced in AAV-IA treated mice (Fig. 3B) . 
AAV-IA mono therapy in woodchucks with chronic WHV infection
WHV is an hepadnavirus closely related to HBV, and woodchucks with chronic WHV infection accurately reproduce the virological and pathological features of CHB, thus representing a relevant preclinical model for testing novel anti-HBV therapies [6] . We generated AAV vectors encoding woodchuck IFNa (AAV-wIFN) and woodchuck IA (AAV-wIA) and groups of two animals were treated by intrahepatic injection of a single dose of either 1.25 Â 10 11 or 1.25 Â 10 12 vg of AAV-wIFN or AAV-wIA. In relation to animal weight, this dose was inferior to that given to mice. This is because of our previous observations (unpublished data) that the woodchuck liver is very easily transduced when the vector is given by intrahepatic injection. Following vector administration, IFNa bioactivity was measured by determining the ability of serial dilutions of serum to protect WHC17 cells, a woodchuck hepatic cell line, against the cytopathic effect of EMCV ( Supplementary Fig. 5 ). As shown in Fig. 4A , we observed a dose-dependent increase in serum IFNa, with levels that were comparable between woodchucks treated with AAV-wIFN or AAV-wIA. However, all four woodchucks treated with AAV-wIFN, independently of the dose, needed to be euthanized because of severe pancytopenia (Fig. 4B, C and D) . This was in contrast to the four woodchucks that received AAV-wIA that survived during the study, except for one animal that was euthanized because of the development of hepatocellular carcinoma, a frequent finding in woodchucks with chronic WHV infection. Notably, in AAV-wIA-treated animals, we observed no remarkable changes in red blood cell counts and only a moderate reduction of leukocytes and platelets in some woodchucks followed by posterior recovery in some of them. In all groups treated with AAV-wIA or AAV-wIFN, ALT levels did not show significant changes with respect to basal levels (data not shown).
All woodchucks in this study exhibited very high viremia, with levels between 10 11 and 10 13 vg/ml. In agreement with reports indicating that an elevated viral load is associated with poor response to IFNa therapy in the woodchuck model [14] , we observed little changes in circulating WHV DNA in all treatment groups (Fig. 5) . Only the woodchuck that was euthanized due to the development of hepatocellular carcinoma showed a drop in viral load of greater than 2 logs from pretreatment values.
Combination therapy with ETV and AAV-IA in woodchucks with chronic WHV infection
As high viral loads, such as those present in woodchucks with chronic WHV infection (Fig. 5) , impair the response to IFNa [14] , we tested the effect of AAV-IA in combination with 0.5 mg/kg ETV for 4 weeks in order to lower viral load during this period of time. In this study, animals (n = 5 per group) received a single dose of 5 Â 10 12 vg of AAV-wIA or the control vector AAV-wApo (encoding woodchuck apoA-I) and ETV therapy was initiated immediately after vector injection. In this experiment, technical reasons obliged to use the intravenous route for vector administration and for this reason the dose administered was higher than in the previous study. Treated woodchucks were followed-up for 16 weeks. We found that ETV treatment resulted in a marked decline in viremia in all animals (between 4 and 6 log 10 from pretreatment), accompanied by a moderate reduction of circulating WHsAg (Fig. 6) . Upon ETV discontinuation, two animals in the control group died following a liver biopsy at week 6, but the other three animals showed a rapid relapse in viremia and antigenemia to pretreatment levels. In AAV-wIA treated woodchucks, however, the rebound of WHV DNA and WHsAg was delayed for several weeks (Fig. 6 ). In two woodchucks (M15IVIA and F16IVIA), serum WHV DNA never reached pretreatment values and remained at reduced levels of 1.34 and 1.10 log 10 , respectively, at the end of the follow-up period at week 16 (Fig. 6 ). The relapse in WHV DNA and WHsAg after ETV discontinuation was significantly lower in AAV-wIA treated woodchucks than in control animals (p <0.0001). Notably, these antiviral effects were achieved with serum IFNa levels that were below the detection threshold of our assay (data not shown). Consonant with this observation, no significant changes in blood cell counts (leukocytes, erythrocytes, and platelets) nor in other biochemical alterations including renal and liver function parameters were found in treated or control animals (data not shown). Thus, combination treatment with ETV and AAV-wIA was safe and achieved significant antiviral effects in a very difficult-to-treat model of chronic hepadnavirus infection.
Discussion
The introduction of effective NAs possessing a high barrier to viral resistance such as ETV or tenofovir has undoubtedly represented a formidable progress in the fight against HBV infection. However, treatment of CHB is still challenging since these drugs do not affect transcription of viral proteins from covalently-closed circular DNA molecule of HBV [15] , nor exert direct immunostimulatory effects to facilitate immune clearance of HBV-infected hepatocytes (15) . Persistent antigenemia despite NAs therapy favours the maintenance of immune tolerance to the virus and, as a result, rebound of HBV replication is frequently observed following the cessation of therapy [3] . Thus, treatment needs to be maintained for an indefinite period of time to ensure sustained control of HBV infection. PegIFNa is an effective drug for treatment of chronic HBV infection as it inhibits HBV replication as well as HBV transcription. In addition, IFNa possesses immunostimulatory properties that facilitate the activation of anti-HBV T cell immune responses. However, the use of IFNa is limited by severe toxicity in a majority of patients [16] . Thus, in the present work, we have tested a protein that is formed by the fusion of IFNa to apoA-I (termed IA) as a potential therapy for CHB. Previously, we have shown that IA displays immunostimulatory activities without inducing hematological toxicity [4] . Because of the favourable toxicology profile of IA, we now investigated if this protein could be administered to the liver by gene transfer. In this study we used a serotype 8 AAV vector. This is a hepatotropic long-term expression vector that has been used in the clinic for the treatment of hemophilia B with remarkable success and excellent tolerance [17] . We found that the AAV vector encoding IA (AAV-IA) was able to protect normal mice against a lethal challenge of EMCV as efficiently as an AAV vector encoding IFNa only (AAV-IFN). AAV-IA was also comparable to AAV-IFN in the control of HBV transcription and replication in HBVTg mice. Notably, AAV-IFN induced severe leukopenia and thrombocytopenia and moderate anemia in treated animals while AAV-IA therapy was associated with minor changes in the platelet count, slight anemia and moderate leukopenia. Because of these encouraging results, AAV-IA was compared to AAV-IFN in woodchucks with chronic WHV infection using the appropriate woodchuck apoA-I and IFNa gene sequences. In the first study, the vectors (AAV-wIA and AAV-wIFN) were administered at two different doses by intrahepatic injection (a route which ensures high transduction efficiency) [18] . We could again confirm the hematological toxicity risk associated with the intrahepatic expression of IFNa at high levels that caused death of all animals. In contrast, AAV-wIA did not produce relevant hematological changes, and all animals survived suggesting that this transgene may be suitable for † † † † WHV (vg/ml) clinical application. However, neither AAV-wIFN nor AAV-wIA promoted any significant decline in viremia in the treated woodchucks. This was not surprising as these animals exhibited extremely high viral loads and it has been shown that the level of viremia is the main factor that negatively predicts the antiviral response to IFN [14] . As viremia is in the range of 10 11 and 10 13 vg/ml in woodchucks with chronic WHV infection while viral load in patients with CHB rarely exceeds 10 7 vg/ml [6] , we designed a new protocol combining AAV-IA (or the control vector AAV-Apo) with 4 weeks of treatment with ETV. In this protocol, we selected the intravenous route for vector administration as this would be more acceptable for clinical use. Using this route, the transduction efficiency was lower compared to previous protocols, and in fact serum IFNa levels were below the detectable threshold. In this study, we did not observe any toxicity related to vector administration but we found a significant enhancement and prolongation of the antiviral effect of ETV in such a way that the decrease of viremia persisted during several weeks after ETV interruption in animals that received AAV-IA while viremia relapsed rapidly to basal values in animals treated with the control vector. It seems possible that by increasing liver transduction with AAV-IA (using a higher vector dose or a different administration route) or by prolonging ETV treatment, we may control chronic WHV infection in a more efficient and sustained manner.
To conclude, our results show in two different animal models that a non-toxic IFNa-based therapy can be administered in combination with NAs for more stringent control of hepadnavirus infection. In our study, we have used a gene therapy approach to ensure sustained intrahepatic expression of IA, but it seems possible that similar results could be obtained by combining ETV with repeated periodic injections of recombinant IA which is easier to use in clinical practice. However, the gene therapy option should not be ruled out for difficult-to-treat cases considering the excellent tolerance demonstrated by AAV vectors in different clinical trials [19, 20] , the possibility of employing inducible promoters and the fact that liver-directed gene therapy would allow attaining high intrahepatic IA concentration without unduly increasing systemic levels. 
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